Protective Effects of Sumatriptan on Renal Ischemia-reperfusion Injury in Male Rats
Mohammad Sheibani1, Yaser Azizi2,3, Maryam Shayan4,5, Sadaf Nezamoleslami4,5, Faezeh Eslami4,5, Nafise Noroozi4,5, Hasan Yousefi-Manesh4,5, Amin Ohadi4,5, Fereshteh Dalouchi3 and Ahmad Reza Dehpour4,5*
1Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2Physiology Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran
*Corresponding Author: Ahmad Reza Dehpour, Professor, Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
November 03, 2021; Published: November 12, 2021
Aim: The production of pro-inflammatory cytokines is one of the underlying reasons for renal ischemia/reperfusion injury (RIRI) that can cause functional disorders in the kidneys. Anti-inflammatory effects of sumatriptan had proved in previous studies. In this study, we aimed to evaluate the protective effect of sumatriptan on renal ischemia/reperfusion injury in rats.
Methods: Both renal arteries of animals in ischemia/reperfusion (I/R) groups clamped by clips for 45 minutes. In pretreatment groups with a single dose of sumatriptan, animals received 0.1, 0.3, 1, and 3 mg/kg doses 30 minutes before I/R. Finally, after 24 hours, renal functional markers (BUN, Creatinine (Cr), Lactate Dehydrogenase (LDH), serum level of inflammatory mediators (TNF-α, IL-1β, and NF-κB), tissue levels of oxidative factors (MDA and MPO), and histopathological changes were evaluated.
Results: Sumatriptan at the doses of 0.1, 0.3, and 1 mg/kg could significantly decrease the inflammatory factors like TNF-α, IL-1β, and NF-κB. The MDA and MPO tissue levels were respectively reduced considerably at (0.3 and 1 mg/kg) and (0.3, 0.1, and 1 mg/kg) doses. All treatment groups showed a significant decrease in serum BUN levels. Sumatriptan treatment also reduced Cr and LDH serum levels at (0.3 mg/kg) and (0.3 and 1 mg/kg) doses, respectively. Treatment of rats with 0.3 mg/kg sumatriptan resulted in remarkable improvement in histopathological damage compared to the I/R group.
Conclusion: Our observation suggests that treatment with low doses of sumatriptan attenuates renal I/R injuries through its anti-inflammatory and anti-oxidative properties.
Keywords: Sumatriptan; Renal Ischemia/Reperfusion; Inflammation; TNF-α; IL-1β; NF-κB; MDA; MPO; Cr; BUN
- Nezamoleslami S., et al. “Protective effect of dapsone against renal ischemia-reperfusion injury in rat”. Immunopharmacology and Immunotoxicology 42 (2020): 1-8.
- Thurman JM. “Triggers of inflammation after renal ischemia/reperfusion”. Clinical Immunology1 (2007): 7-13.
- Williams P., et al. “Characterization of renal ischemia-reperfusion injury in rats”. Journal of Pharmacological and Toxicological Methods1 (1997): 1-7.
- Sung FL., et al. “Enhanced MCP-1 expression during ischemia/reperfusion injury is mediated by oxidative stress and NF-κB”. Kidney International4 (2002): 1160-1170.
- Takada M., et al. “The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand”. Journal of Clinical Investigation 11 (1997): 2682-2690.
- Donnahoo KK., et al. “Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion”. American Journal of Physiology 3 (1999): R922-929.
- Kianian F., et al. “Protective effects of celecoxib on ischemia reperfusion–induced acute kidney injury: comparing between male and female rats”. Iranian Journal of Basic Medical Sciences 1 (2019): 43.
- Sole MJ., et al. “An active pathway for serotonin synthesis by renal proximal tubules”. Kidney International 3 (1986): 689-694.
- Eslami F., et al. “Sumatriptan Reduces Severity of Status Epilepticus Induced by Lithium‐Pilocarpine Through Nitrergic Transmission and 5‐HT 1B/D Receptors in Rats: A Pharmacological‐Based Evidence”. Fundamental and Clinical Pharmacology 1(2020): 131-140.
- Dehpour AR., et al. “Evaluation of Anti-inflammatory and Antioxidant Effects of Sumatriptan on Carbon Tetrachloride-induced Hepatotoxicity in Rats”. Drug Research (2021).
- Afshari K., et al. “Sumatriptan improves the locomotor activity and neuropathic pain by modulating neuroinflammation in rat model of spinal cord injury”. Neurological Research 1 (2021): 29-39.
- Sheibani M., et al. “Sumatriptan protects against myocardial ischaemia–reperfusion injury by inhibition of inflammation in rat model”. Inflammopharmacology 5 (2019): 1071-1080.
- Dejban P., et al. “Protective effects of sumatriptan on ischaemia/reperfusion injury following torsion/detorsion in ipsilateral and contralateral testes of rat”. Andrologia9 (2019): e13358.
- Mobasheran P., et al. “The effects of acute Sumatriptan treatment on renal ischemia/reperfusion injury in rat and the possible involvement of nitric oxide”. Canadian Journal of Physiology and Pharmacology4 (2019): 252-258.
- Aryannejad A., et al. “Protective effect of modafinil on skin flap survival in the experimental random-pattern skin flap model in rats: The role of ATP-sensitive potassium channels and nitric oxide pathway”. Journal of Plastic, Reconstructive and Aesthetic Surgery6 (2021): 1346-1354.
- Tabary M., et al. “Ivermectin Increases Random-Pattern Skin Flap Survival in Rats: The Novel Role of GABAergic System”. Journal of Surgical Research 259 (2021): 431-441.
- Ohkawa H., et al. “Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction”. Analytical Biochemistry2 (1979): 351-358.
- Shokrian Zeini M., et al. “Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation”. International Immunopharmacology 100 (2021): 108160.
- Amanlou A., et al. “Anticonvulsive evaluation and histopathological survey of thalidomide synthetic analogs on lithium-pilocarpine-induced status epilepticus in rats”. Research in Pharmaceutical Sciences6 (2021): 586-595.
- Aryannejad A., et al. “Anti-inflammatory Effects of Ivermectin in the Treatment of Acetic Acid Induced Colitis in Rats: Involvement of GABAB Receptors”. Digestive Diseases and Sciences (2021).
- Salvadori M., et al. “Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment”. World Journal of Transplantation2 (2015): 52-67.
- Xu Z., et al. “Dexmedetomidine attenuates renal and myocardial ischemia/reperfusion injury in a dose-dependent manner by inhibiting inflammatory response”. Annals of Clinical and Laboratory Science1 (2019): 31-35.
- Bonventre JV and Yang L. “Cellular pathophysiology of ischemic acute kidney injury”. The Journal of Clinical Investigation 11 (2011): 4210-4221.
- Pucino V., et al. “Lactate at the crossroads of metabolism, inflammation, and autoimmunity”. European Journal of Immunology 1(2017): 14-21.
- Friedewald JJ and Rabb H. “Inflammatory cells in ischemic acute renal failure”. Kidney International 2 (2004): 486-491.
- Bonventre JV and Zuk A. “Ischemic acute renal failure: an inflammatory disease?”. Kidney International 2 (2004): 480-485.
- Liu S., et al. “Trehalose attenuates renal ischemia-reperfusion injury by enhancing autophagy and inhibiting oxidative stress and inflammation”. American Journal of Physiology-Renal Physiology4 (2020): F994-F1005.
- Franco-Acevedo A., et al. “Opioid Preconditioning Modulates Repair Responses to Prevent Renal Ischemia-Reperfusion Injury”. Pharmaceuticals11 (2020): 387.
- Habibey R and Pazoki-Toroudi H. “Morphine dependence protects rat kidney against ischaemia–reperfusion injury”. Clinical and Experimental Pharmacology and Physiology10 (2008): 1209-1214.
- Zamanian G., et al. “Interaction of morphine tolerance with pentylenetetrazole-induced seizure threshold in mice: The role of NMDA-receptor/NO pathway”. Epilepsy and Behavior 112 (2020): 107343.
- DONNAHOO KK., et al. “Early renal ischemia, with or without reperfusion, activates NFκB and increases TNF-α bioactivity in the kidney”. The Journal of Urology 163 .4 (2000): 1328-1332.
- Xin Y., et al. “AS-IV protects against kidney IRI through inhibition of NF-κB activity and PUMA upregulation”. International journal of clinical and Experimental Medicine10 (2015): 18293.
- Jaeschke H and Woolbright BL. “Current strategies to minimize hepatic ischemia–reperfusion injury by targeting reactive oxygen species”. Transplantation Reviews2 (2012): 103-114.
- Lashgari N-A., et al. “Current overview of opioids in progression of inflammatory bowel disease pharmacological and clinical considerations”. Molecular Biology Reports1 (2021): 855-874.
- Burne-Taney MJ., et al. “Acute renal failure after whole body ischemia is characterized by inflammation and T cell-mediated injury”. The American Journal of Physiology-Renal Physiology1 (2003): F87-94.
- Malle E., et al. “Myeloperoxidase in kidney disease”. Kidney international6(2003): 1956-1967.
- Gaweł S., et al. “Malondialdehyde (MDA) as a lipid peroxidation marker”. Wiadomosci lekarskie (Warsaw, Poland: 1960) 57.9-10 (2004): 453-455.
- Gharishvandi F., et al. “Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in intestinal ischemia/reperfusion in rats”. European Journal of Pharmacology 882 (2020): 173265.
- Hernandez LA., et al. “Role of neutrophils in ischemia-reperfusion-induced microvascular injury”. American Journal of Physiology-Heart and Circulatory Physiology3 (1987): H699-H703.
- Khalilzadeh M., et al. “The protective effects of sumatriptan on vincristine-induced peripheral neuropathy in a rat model”. Neurotoxicology 67 (2018): 279-286.
- Sheibani M., et al. “Anti-Inflammatory and Antioxidative Effects of Sumatriptan Against Doxorubicin-Induced Cardiotoxicity in Rat”. Acta Medica Iranica7 (2021).